Year: 2008
Type: dissertation
Abstract: Breast cancer is one of the leading causes of death of women in western countries. \nIt affects one out of eight females in the USA (1) and one out of nine females in The \nNetherlands (www.kankerregistratie.nl) during their lifetime. Many risk factors for breast \ncancer have been identified including gender, familial susceptibility, age, and exposure \nto hormones i.e. use of exogenous hormones, young age at menarge, and high age at \nmenopause and first pregnancy (2). Familial breast cancer accounts for 5-10% of total \nbreast cancer. The remaining 90-95% are called “sporadic”. Occasionally breast cancer \nalso affects males (1% of the breast-cancer incidence in women). \nIn The Netherlands there are approximately 12000 new cases and about 3300 deaths \nyearly as a result of the disease. Since 1994, the mortality has slightly decreased due \nto earlier detection, following the introduction of the national breast cancer-screening \nprogram, and better treatment strategies (http://www.rivm.nl). Breast cancer patients \nmay be subjected to various treatments including surgery, radiation, chemotherapy, \nmolecular targeted therapy, or endocrine (hormonal) therapy. Often treatment strategies \nare combined. Surgery forms a part of nearly every patient’s treatment for breast cancer, \nresulting in partial removal (lumpectomy) or total removal of the breast (mastectomy). \nRadiation may be used before or after surgery, and may accompany chemotherapy. In \nmolecular targeted therapy, compounds like monoclonal antibodies or small tyrosine \nkinase inhibitors inhibit a specific target molecule. In contrast to conventional chemotherapy, \nwhich acts on all dividing cells generating toxic effects and damage of normal \ntissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells \ndirectly involved in tumor progression. Endocrine therapy works by interfering with the \nestrogen pathway that enhances cell-proliferation. It is applied for prevention, adjuvant \ntherapy, and for treatment of metastatic cancers in patients with hormone receptorpositive \ntumors (3, 4).
Author: Daniëlle Meijer
Institution: Erasmus University Rotterdam
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1572694336
